

CITATION REPORT

List of articles citing

Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients

DOI: 10.1097/ftd.ob013e3181838063

Therapeutic Drug Monitoring, 2008, 30, 559-64.

Source: <https://exaly.com/paper-pdf/45049672/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
71	No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 1047-53	2.8	26
70	Telmisartan pharmacokinetics in Japanese renal transplant recipients. <i>Clinica Chimica Acta</i> , 2009 , 399, 83-7	6.2	29
69	Limited sampling strategies for mycophenolic acid in solid organ transplantation: a systematic review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 1079-97	5.5	18
68	New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 416-35	3.2	124
67	Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study. <i>Pharmacotherapy</i> , 2010 , 30, 1097-108	5.8	18
66	The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 87, 100-8	6.1	123
65	Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 341-58	6.9	226
64	SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. <i>Pharmacogenomics</i> , 2010 , 11, 1703-13	2.6	40
63	Pharmacogenetic influences on mycophenolate therapy. <i>Pharmacogenomics</i> , 2010 , 11, 369-90	2.6	42
62	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. <i>Pharmacological Reviews</i> , 2011 , 63, 157-81	22.5	465
61	CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. <i>Transplantation</i> , 2011 , 91, 652-6	1.8	53
60	Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2011 , 46, 90-7	4.4	10
59	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. <i>Transplantation Reviews</i> , 2011 , 25, 47-57	3.3	89
58	Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report. <i>Transplantation Reviews</i> , 2011 , 25, 65-77	3.3	20
57	Research highlights. SNPs affecting efficacy and safety of statin therapy. <i>Pharmacogenomics</i> , 2011 , 12, 773-8	2.6	
56	Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 103-14	1.9	66
55	ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. <i>Clinica Chimica Acta</i> , 2012 , 413, 1326-37	6.2	25

54	The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals. <i>Clinica Chimica Acta</i> , 2012 , 413, 683-90	6.2	36
53	The influence of UGT polymorphisms as biomarkers in solid organ transplantation. <i>Clinica Chimica Acta</i> , 2012 , 413, 1318-25	6.2	24
52	Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 303-31	6.2	47
51	Pharmacokinetic drug interactions involving Ginkgo biloba. <i>Drug Metabolism Reviews</i> , 2013 , 45, 353-85	7	59
50	Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 463-75	3.8	23
49	Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs. <i>Pharmacogenomics</i> , 2013 , 14, 1099-118	2.6	29
48	Pharmacogenetics and immunosuppressive drugs. <i>Expert Review of Clinical Pharmacology</i> , 2014 , 7, 821-358	3.8	9
47	Expression of IMPDH mRNA after mycophenolate administration in male volunteers. <i>BioMed Research International</i> , 2014 , 2014, 870209	3	1
46	Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?. <i>Transplant International</i> , 2014 , 27, 994-1004	3	22
45	Genotype and allele frequencies of drug-metabolizing enzymes and drug transporter genes affecting immunosuppressants in the Spanish white population. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 159-68	3.2	14
44	How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 227-245	6.2	9
43	Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 1211-9	2.8	15
42	A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China. <i>Transplantation Proceedings</i> , 2014 , 46, 1362-5	1.1	15
41	Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. <i>Archives of Toxicology</i> , 2014 , 88, 1351-89	5.8	115
40	Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib. <i>Biomarker Research</i> , 2014 , 2, 6	8	18
39	Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus. <i>Translational Research</i> , 2014 , 164, 46-56	11	24
38	Limited sampling strategy for predicting area under the concentration-time curve for mycophenolic Acid in Chinese adults receiving mycophenolate mofetil and tacrolimus early after renal transplantation. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 304-10	3.2	11
37	Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation. <i>Disease Markers</i> , 2015 , 2015, 179434	3.2	5

36	Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , 2016 , 38 Suppl 1, S57-69	3.2	39
35	Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings. <i>Journal of Pharmaceutical Sciences</i> , 2017 , 106, 2312-2325	3.9	68
34	Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients and donors PABCC2 gene variants, and their interactions. <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 1129-1140	2.8	7
33	Association of UGT2B7, UGT1A9, ABCG2, and IL23R polymorphisms with rejection risk in kidney transplant patients. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2017 , 80, 661-671	3.2	7
32	Meta-analysis reveals a lack of association between MRP2 C-24T genetic polymorphism and the pharmacokinetics of mycophenolic acid in adult renal transplant recipients. <i>Meta Gene</i> , 2017 , 11, 91-97	0.7	1
31	Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population. <i>Scientific Reports</i> , 2017 , 7, 17379	4.9	3
30	Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation. <i>Xenobiotica</i> , 2017 , 47, 916-922	2	8
29	Expression, regulation and function of intestinal drug transporters: an update. <i>Biological Chemistry</i> , 2017 , 398, 175-192	4.5	66
28	Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class III or IV: A single-centre retrospective study. <i>PLoS ONE</i> , 2017 , 12, e0175152	3.7	10
27	Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan. <i>International Journal of Hematology</i> , 2018 , 108, 176-183	2.3	3
26	Gene Polymorphisms of Immunosuppressants in Solid Organ Transplantation. 2018 ,		
25	OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide. <i>Scientific Reports</i> , 2018 , 8, 18063	4.9	6
24	Polymorphisms of the Multidrug Pump ABCG2: A Systematic Review of Their Effect on Protein Expression, Function, and Drug Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 1886-1899 ⁴		44
23	Impact of UGT2B7 and ABCG2 genetic polymorphisms on mycophenolic acid metabolism in Chinese renal transplant recipients. <i>Pharmacogenomics</i> , 2018 , 19, 1323-1334	2.6	7
22	Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2018 , 18, e1173-e1179	3	4
21	OATP1B3-1B7 (LST-3TM12) Is a Drug Transporter That Affects Endoplasmic Reticulum Access and the Metabolism of Ezetimibe. <i>Molecular Pharmacology</i> , 2019 , 96, 128-137	4.3	5
20	Pharmacokinetic Drug-Drug Interactions Between Letemovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil. <i>Journal of Clinical Pharmacology</i> , 2019 , 59, 1331-1339	2.9	27
19	Mycophenolic Acid and Its Pharmacokinetic Drug-Drug Interactions in Humans: Review of the Evidence and Clinical Implications. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 295-311	2.9	11

18	Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. <i>Scientific Reports</i> , 2020 , 10, 13486	4.9	9
17	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 150-200	3.2	17
16	Influence of SLCO1B1 521T>C, UGT2B7 802C>T and IMPDH1 -106G>A Genetic Polymorphisms on Mycophenolic Acid Levels and Adverse Reactions in Chinese Autoimmune Disease Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021 , 14, 713-722	2.1	2
15	The Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid: Systematic Review and Meta-analysis. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1291-1302	6.2	3
14	Genetic polymorphisms in metabolic enzymes and transporters have no impact on mycophenolic acid pharmacokinetics in adult kidney transplant patients co-treated with tacrolimus: A population analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 1564-1575	2.2	0
13	Effect of polymorphisms on pharmacokinetics and adverse reactions of mycophenolic acid in kidney transplant patients. <i>Pharmacogenomics</i> , 2021 , 22, 1019-1040	2.6	2
12	A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014 , 52, 303-13	2	3
11	Pharmacogenetics of immunosuppressant drugs: A new aspect for individualized therapy. <i>World Journal of Transplantation</i> , 2020 , 10, 90-103	2.3	3
10	SLCO1B3 polymorphisms and clinical outcomes in kidney transplant recipients receiving mycophenolate. <i>Pharmacogenomics</i> , 2021 , 22, 1111-1120	2.6	0
9	Pharmacogenomics of Immunosuppressants. 70-97		
8	Pharmacogenomics of Immunosuppressants. 2020 , 83-106		
7	Human ABCG2: structure, function, and its role in multidrug resistance. <i>International Journal of Biochemistry and Molecular Biology</i> , 2012 , 3, 1-27	0.4	122
6	The Role of Uptake and Efflux Transporters in the Disposition of Glucuronide and Sulfate Conjugates.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 802539	5.6	4
5	Recent lessons learned from population pharmacokinetic studies of mycophenolic acid: physiological, genomic, and drug interactions leading to the prediction of drug effects.. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022 ,	5.5	0
4	SLCO1B1 c.521T>C gene polymorphism decreases hypoglycemia risk in sulfonylurea-treated type 2 diabetic patients. 2022 ,		0
3	Loss of function ABCG2 c.421C>A (rs2231142) polymorphism increases steady-state exposure to mycophenolic acid in stable renal transplant recipients: exploratory matched cohort study.		0
2	Loss of Function ABCG2 c.421C>A (rs2231142) Polymorphism Increases Steady-State Exposure to Mycophenolic Acid in Stable Renal Transplant Recipients: An Exploratory Matched Cohort Study.		0
1	SLCO1B3 T334G polymorphisms and mycophenolate mofetil-related adverse reactions in kidney transplant recipients.		0

